| 臺大學術典藏 |
2020-05-26T09:26:42Z |
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
|
Bai Y; Rabbie S; Kim D.-W; Ahn M.-J; CHIH-HSIN YANG; Zhang X.; Zhang X.;Chih-Hsin Yang;Ahn M.-J;Kim D.-W;Rabbie S;Bai Y;Yin X;Xu Y;Cheng Z;Zhang L;Chen K;Wang Y;Guo Q;Yang Z; Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
|
Bai Y; Rabbie S; Kim D.-W; Ahn M.-J; CHIH-HSIN YANG; Zhang X.; Zhang X.;Chih-Hsin Yang;Ahn M.-J;Kim D.-W;Rabbie S;Bai Y;Yin X;Xu Y;Cheng Z;Zhang L;Chen K;Wang Y;Guo Q;Yang Z; Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
Scientific Advances in Thoracic Oncology 2016
|
Spigel D.R.;Hirsch F.R;Gandara D.R;Scagliotti G.V;Leighl N.B;Kelly R.J;Baas P;Tsao A;Rudin C.M;Faivre-Finn C;Wynes M.W;Peters S;Gettinger S;Horn L;Patel J.D;Costa D.B;Ahn M.-J;Shaw A.T;Sequist L.V;Chih-Hsin Yang;Johnson M;Kim D.-W;Solomon B;Senan S;Higgins K;Wu Y.-L;Wakelee H.A;Donington J;Asamura H;Lim E;Detterbeck F.C;Rami-Porta R;Dacic S;Bubendorf L;Yatabe Y;Mulshine J.L;Groen H.J.M;Field J.K;Jett J.R;Cummings K.M;Stone E.C.A;Soo R.A; Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
Scientific Advances in Thoracic Oncology 2016
|
Spigel D.R.;Hirsch F.R;Gandara D.R;Scagliotti G.V;Leighl N.B;Kelly R.J;Baas P;Tsao A;Rudin C.M;Faivre-Finn C;Wynes M.W;Peters S;Gettinger S;Horn L;Patel J.D;Costa D.B;Ahn M.-J;Shaw A.T;Sequist L.V;Chih-Hsin Yang;Johnson M;Kim D.-W;Solomon B;Senan S;Higgins K;Wu Y.-L;Wakelee H.A;Donington J;Asamura H;Lim E;Detterbeck F.C;Rami-Porta R;Dacic S;Bubendorf L;Yatabe Y;Mulshine J.L;Groen H.J.M;Field J.K;Jett J.R;Cummings K.M;Stone E.C.A;Soo R.A; Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Phase II study of crizotinib in east asian patients with ROS1-positive advanced non?�small-cell lung cancer
|
Goto K.;Wilner K.D;Usari T;Paolini J;Roychowdhury D;Kemner A;Yamanaka T;Takahashi T;Ahn M.-J;Yamamoto N;Yang J.-J;Seto T;Zhou J;Lu S;Kim D.-W;Chih-Hsin Yang;Wu Y.-L; Wu Y.-L; CHIH-HSIN YANG; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Phase II study of crizotinib in east asian patients with ROS1-positive advanced non?�small-cell lung cancer
|
Goto K.;Wilner K.D;Usari T;Paolini J;Roychowdhury D;Kemner A;Yamanaka T;Takahashi T;Ahn M.-J;Yamamoto N;Yang J.-J;Seto T;Zhou J;Lu S;Kim D.-W;Chih-Hsin Yang;Wu Y.-L; Wu Y.-L; CHIH-HSIN YANG; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
